Posted by Michael Wonder on 30 Oct 2023
ICER publishes final evidence report on gene therapy for metachromatic leukodystrophy
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when compared to usual care; arsa-cel would achieve common thresholds for cost-effectiveness if priced between $2.3 million - $3.9 million.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of atidarsagene autotemcel (Orchard Therapeutics) for metachromatic leukodystrophy.
